Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy

NCT05404906 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT05404906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05404906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy
Lead sponsor
The First Affiliated Hospital of Soochow University
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 25, 2022
Completion date
June 30, 2030
Enrollment
124 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml) in remission